logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10183912 B1

PDFFull Text
Date of Patent:
Jan. 22, 2019

Filed:

Mar. 31, 2015

Hdmx inhibitors and their use for cancer treatment

Applicant:

Mirx Pharmaceuticals, Llc, Lexington, KY (US);

Inventors:

David Wald, Shaker Heights, OH (US);

Mukesh Agarwal, Solon, OH (US);

Zhiqing Xia, Lexington, KY (US);

Goutam Karan, Lexington, KY (US);

Mahesh Gundluru, Louisville, KY (US);

Assignee:

MIRX PHARMACEUTICALS, LLC, Lexington, KY (US);

Attorney:

King & Schickli, PLLC

Primary Examiner:

Yevgeny Valenrod

Int. Cl.
CPC ...
C07D 219/02 (2006.01); A61K 31/473 (2006.01); A61K 31/496 (2006.01); A61K 45/06 (2006.01); C07D 219/08 (2006.01); C07D 219/10 (2006.01); C07D 219/12 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 417/12 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 219/02 (2013.01); A61K 31/473 (2013.01); A61K 31/496 (2013.01); A61K 45/06 (2013.01); C07D 219/08 (2013.01); C07D 219/10 (2013.01); C07D 219/12 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 417/12 (2013.01); C07D 495/04 (2013.01);
Abstract

The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

Find Patent Forward Citations

Loading…